D-Index & Metrics Best Publications
Alexander G.G. Turpie

Alexander G.G. Turpie

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 110 Citations 62,689 516 World Ranking 3163 National Ranking 125

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Surgery
  • Cardiology

Surgery, Anesthesia, Anticoagulant, Thrombosis and Pulmonary embolism are his primary areas of study. His work on Warfarin expands to the thematically related Surgery. His Anesthesia research is multidisciplinary, incorporating perspectives in Rivaroxaban, Idraparinux, Heparin, Placebo and Complication.

The Anticoagulant study combines topics in areas such as Antithrombotic, Vitamin K antagonist, Randomization, Prospective cohort study and Tinzaparin sodium. His Thrombosis research includes elements of Radiology and Vein. His research investigates the connection between Pulmonary embolism and topics such as Chemotherapy that intersect with problems in Semuloparin, Multicenter trial and Cancer.

His most cited work include:

  • COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS (3355 citations)
  • ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. (1422 citations)
  • A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients (1347 citations)

What are the main themes of his work throughout his whole career to date?

Alexander G.G. Turpie spends much of his time researching Internal medicine, Surgery, Thrombosis, Anesthesia and Pulmonary embolism. His Internal medicine research focuses on Cardiology and how it relates to Aspirin. His research on Surgery frequently connects to adjacent areas such as Warfarin.

His studies in Thrombosis integrate themes in fields like Clinical trial, Radiology, Incidence and Vein. Alexander G.G. Turpie has included themes like Fondaparinux, Low molecular weight heparin, Heparin, Anticoagulant and Placebo in his Anesthesia study. As a member of one scientific family, Alexander G.G. Turpie mostly works in the field of Low molecular weight heparin, focusing on Antithrombotic and, on occasion, Fibrinolytic agent.

He most often published in these fields:

  • Internal medicine (37.17%)
  • Surgery (36.99%)
  • Thrombosis (30.86%)

What were the highlights of his more recent work (between 2014-2021)?

  • Internal medicine (37.17%)
  • Rivaroxaban (15.80%)
  • Atrial fibrillation (12.64%)

In recent papers he was focusing on the following fields of study:

His primary areas of investigation include Internal medicine, Rivaroxaban, Atrial fibrillation, Stroke and Thrombosis. His work in Internal medicine tackles topics such as Cardiology which are related to areas like Lower risk. His studies deal with areas such as Surgery, Discontinuation, Venous thromboembolism and Clinical trial as well as Rivaroxaban.

As part of the same scientific family, Alexander G.G. Turpie usually focuses on Surgery, concentrating on Antithrombotic and intersecting with Fibrinolytic agent. His biological study spans a wide range of topics, including Arthroplasty and Intensive care medicine. His study in Deep vein is interdisciplinary in nature, drawing from both Pulmonary embolism and Heparin.

Between 2014 and 2021, his most popular works were:

  • XANTUS : a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. (297 citations)
  • Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study (168 citations)
  • Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation (150 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Surgery
  • Cardiology

Alexander G.G. Turpie mainly focuses on Internal medicine, Stroke, Atrial fibrillation, Rivaroxaban and Thrombosis. His work deals with themes such as Diabetes mellitus, Prospective cohort study, Cohort and Comorbidity, which intersect with Stroke. Gastrointestinal bleeding and Myocardial infarction is closely connected to Discontinuation in his research, which is encompassed under the umbrella topic of Rivaroxaban.

Thrombosis is a subfield of Surgery that Alexander G.G. Turpie studies. Alexander G.G. Turpie works in the field of Surgery, focusing on Randomized controlled trial in particular. His Deep vein research incorporates elements of Heparin, Anesthesia and Fondaparinux.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS

R Altman;L Carreras;R Diaz;E Figueroa.
BMJ (1994)

6330 Citations

ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group.

R Collins;R Peto;M Flather;S Parish.
The Lancet (1995)

2298 Citations

Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer

Philip S. Wells;David R. Anderson;Marc Rodger;Jeffrey S. Ginsberg.
Thrombosis and Haemostasis (2000)

2127 Citations

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.

M. Cohen;C. Demers;E. P. Gurfinkel;A. G. G. Turpie.
The New England Journal of Medicine (1997)

2065 Citations

A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients

Meyer Michel Samama;Alexander Thomas Cohen;Jean-Yves Darmon;Louis Desjardins.
The New England Journal of Medicine (1999)

2009 Citations

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

Michael R. Lassen;Walter Ageno;Lars C. Borris;Jay R. Lieberman.
The New England Journal of Medicine (2008)

1831 Citations

A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.

Mark Levine;Michael Gent;Jack Hirsh;Jacques Leclerc.
The New England Journal of Medicine (1996)

1615 Citations

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.

E. M. Antman;C. H. Mccabe;E. P. Gurfinkel;A. G. G. Turpie.
Circulation (1999)

1542 Citations

A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.

Clive Kearon;Michael Gent;Michael Gent;Jack Hirsh;Jack Hirsh;Jeffrey Weitz.
The New England Journal of Medicine (1999)

1453 Citations

ISIS-3 - A RANDOMIZED COMPARISON OF STREPTOKINASE VS TISSUE PLASMINOGEN-ACTIVATOR VS ANISTREPLASE AND OF ASPIRIN PLUS HEPARIN VS ASPIRIN ALONE AMONG 41,299 CASES OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION

D Hunt;J Varigos;F Dienstl;P Lechleitner.
The Lancet (1992)

1423 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Alexander G.G. Turpie

Gregory Y.H. Lip

Gregory Y.H. Lip

University of Liverpool

Publications: 371

Jack Hirsh

Jack Hirsh

McMaster University

Publications: 209

Samuel Z. Goldhaber

Samuel Z. Goldhaber

Brigham and Women's Hospital

Publications: 208

Jeffrey S. Ginsberg

Jeffrey S. Ginsberg

McMaster University

Publications: 165

Mark Crowther

Mark Crowther

McMaster University

Publications: 163

James D. Douketis

James D. Douketis

McMaster University

Publications: 151

Harry R. Büller

Harry R. Büller

University of Amsterdam

Publications: 140

Robert M. Califf

Robert M. Califf

Duke University

Publications: 137

Paolo Prandoni

Paolo Prandoni

University of Padua

Publications: 131

Walter Ageno

Walter Ageno

University of Insubria

Publications: 131

Giancarlo Agnelli

Giancarlo Agnelli

University of Perugia

Publications: 130

Jeffrey I. Weitz

Jeffrey I. Weitz

McMaster University

Publications: 126

John W. Eikelboom

John W. Eikelboom

Population Health Research Institute

Publications: 122

Sam Schulman

Sam Schulman

McMaster University

Publications: 115

Clive Kearon

Clive Kearon

McMaster University

Publications: 110

Elliott M. Antman

Elliott M. Antman

Brigham and Women's Hospital

Publications: 107

Trending Scientists

Wolfgang L. Wendland

Wolfgang L. Wendland

University of Stuttgart

Jeffrey F. Morris

Jeffrey F. Morris

City College of New York

Samian Kaur

Samian Kaur

InterDigital (United States)

Werner Kaminsky

Werner Kaminsky

Universität Hamburg

Seijiro Matsubara

Seijiro Matsubara

Kyoto University

William S. York

William S. York

University of Georgia

Xiaodong Zhang

Xiaodong Zhang

Imperial College London

David Etheridge

David Etheridge

Commonwealth Scientific and Industrial Research Organisation

Richard P. Turco

Richard P. Turco

University of California, Los Angeles

Jennifer M. Bossert

Jennifer M. Bossert

National Institute on Drug Abuse

Kevin E. O'Grady

Kevin E. O'Grady

University of Maryland, College Park

Ralph W. Hood

Ralph W. Hood

University of Tennessee at Chattanooga

David Capper

David Capper

Charité - University Medicine Berlin

David C. Musch

David C. Musch

University of Michigan–Ann Arbor

Michael J. O'Connell

Michael J. O'Connell

Mayo Clinic

Joern H. Block

Joern H. Block

University of Trier

Something went wrong. Please try again later.